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1 Introduction 
Nast 
1.1 Notes on use of guideline 
An evidence-based guideline has been defined as ‘a systematically developed 
statement that assists clinicians and patients in making decisions about appropriate 
treatment for a specific condition’ [1]. A guideline will never encompass therapy 
specifications for all medical decision-making situations. Deviation from the 
recommendations may, therefore, be justified in specific situations. 
This is not a textbook on acne, nor a complete, all-inclusive reference on all aspects 
important to the treatment of acne. The presentation on safety in particular is limited 
to the information available in the included clinical trials and does not represent all 
the available and necessary information for the treatment of patients. Additional 
consultation of specific sources of information on the particular intervention 
prescribed (e. g. product information sheet) is necessary. Furthermore, all patients 
should be informed about the specific risks associated with any given topical and/ or 
systemic therapy. 
Readers must carefully check the information in this guideline and determine whether 
the recommendations contained therein (e. g. regarding dose, dosing regimens, 
contraindications, or drug interactions) are complete, correct, and up-to-date. The 
authors and publishers can take no responsibility for dosage or treatment decisions. 
1.2 Objectives of the guideline 
Improvement in the care of acne patients 
The idea behind this guideline is that recommendations based on a systematic 
review of the literature and a structured consensus process will improve the quality of 
acne therapy in general. Personal experiences and traditional therapy concepts 
should be critically evaluated and replaced, if applicable, with the consented 
therapeutic recommendations. In particular, a correct choice of therapy should be 
facilitated by presenting the suitable therapy options in a therapy algorithm, taking 
into account the type of acne and the severity of the disease. 
Reduction of serious conditions and scarring 
As a result of the detailed description of systemic therapies for patients with severe 
acne, reservations about these interventions should be overcome to ensure that 
patients receive the optimal therapy. With the timely introduction of sufficient 
therapies, the development of serious post-acne conditions, severe scarring and 
adverse psychosocial impact should be reduced. 
Promotion of adherence 
Good therapeutic adherence is key to treatment success. Adherence is facilitated by 
knowledge of the product being used, for example treatment duration, the expected 
onset of effect, the sequence of the healing process, the maximal achievable 
average effect, expected adverse events, and the benefit to quality of life. 
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Reduction of antibiotic resistance 
The use of topical and systemic antibiotics should be optimized by using appropriate 
combinations for a predefined duration, in order to reduce the development of 
antibiotic resistance. 
1.3 Target population 
Health care professionals 
This guideline has been developed to help health care professionals provide optimal 
therapy to patients with mild, moderate or severe acne. The primary target groups 
are dermatologists and other professionals involved in the treatment of acne, such as 
paediatricians and general practitioners. The target group may vary with respect to 
national differences in the distribution of services provided by specialists or general 
practitioners. 
Patients 
The recommendations of the guideline refer to patients who suffer from acne. These 
are mainly adolescents treated in outpatient clinics. The appropriate therapy option is 
presented according to the type of acne that is present. The primary focus is the 
induction therapy of facial acne, recommendations also encompass patients with 
more widespread acne affecting the trunk (see Chapter 1.6). Non-primary target 
groups are patients with special forms of acne, such as, occupational acne, 
chloracne, acne aestivalis, acne neonatorum and acne inverse (hidradenitis 
suppurativa). 
1.4 Pharmacoeconomic considerations 
European guidelines are intended for adaptation to national conditions. It is beyond 
the scope of this guideline to take into consideration the specific costs and 
reimbursement situations in every European country. Differences in prices, 
reimbursement systems, willingness and ability to pay for medication among patients 
and the availability of generics are too large. Therefore, pharmacoeconomic 
considerations will have to be taken into account when guidelines are developed at 
national and local levels. 
The personal financial and health insurance situation of a patient may necessitate 
amendments to the prioritisation of treatment recommendations. However, if financial 
resources allow, the suggested ranking in the therapeutic algorithm should be 
pursued. 
1.5 Considerations with respect to vehicle for topical treatments 
The skin type, the sex and stage of disease has to be taken into consideration when 
choosing the vehicle for topical treatments. The efficacy and safety/ tolerability of 
topical treatments are influenced by the choice of vehicle. 
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1.6 Considerations regarding area of involvement 
The face is the primary region of interest for the treatment of acne. Appearance, 
scarring, quality of life and social stigmatization are important considerations when 
dealing with facial dermatological diseases. 
The recommendations of this guideline apply primarily to the treatment of facial acne. 
More widespread involvement will certainly favour earlier use of a systemic treatment 
due to the efficacy and practicability of such treatments. 
1.7 Clinical features and variants 
Layton/ Finlay 
Acne (synonym “acne vulgaris”) is a polymorphic, inflammatory skin disease nearly 
always affecting the face (99 % of cases). It also commonly affects the back (60 %) 
and chest (15 %) [2]. Seborrhoea is a frequent feature [3]. 
The clinical picture embraces a spectrum of signs, ranging from mild comedonal 
acne, with or without sparse inflammatory lesions (IL), to acne conglobate or 
aggressive fulminate disease with deep-seated inflammation, nodules and in some 
cases associated systemic symptoms. 
1.7.1 Comedonal acne 
Clinically non-inflamed lesions develop from the subclinical microcomedo which is 
evident on histological examination early in acne development [2]. Non-inflamed 
lesions encompass both open (blackheads) and closed comedones (whiteheads). 
Comedones frequently have a mid-facial distribution in childhood and, when evident 
early in the course of the disease, this pattern is indicative of poor prognosis [4]. 
Closed comedones are often inconspicuous with no visible follicular opening. 
1.7.2 Papulopustular acne 
Most patients have a mixture of non-inflammatory (NIL) and inflammatory lesions [5]. 
Inflammatory lesions arise from the microcomedo or from non-inflammatory clinically 
apparent lesions and may be either superficial or deep [6]. Superficial inflammatory 
lesions include papules and pustules (5 mm or less in diameter). These may evolve 
into nodules in more severe disease. Inflammatory macules represent regressing 
lesions that may persist for many weeks and contribute markedly to the general 
inflammatory appearance [5]. 
1.7.3 Nodular/ conglobate acne 
Nodules are defined as firm, inflamed lesions >10 mm diameter, painful by palpation. 
[7]. They may extend deeply and over large areas, frequently resulting in painful 
lesions, exudative sinus tracts and tissue destruction. Conglobate acne is a rare but 
severe form of acne found most commonly in adult males with few or no systemic 
symptoms. Lesions usually occur on the trunk and upper limbs and frequently extend 
to the buttocks. In contrast to ordinary acne, facial lesions are less common. The 
condition often presents in the second to third decade of life and may persist into the 
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sixth decade. Conglobate acne is characterized by multiple grouped comedones 
amidst inflammatory papules, tender, suppurative nodules which commonly coalesce 
to form sinus tracts. Extensive and disfiguring scarring is frequently a feature. 
1.7.4 Other acne variants 
There are several severe and unusual variants or complications of acne as well as 
other similar diseases. These include acne fulminans, gram-negative folliculitis, 
rosacea fulminans, vasculitis, mechanical acne, oil/ tar acne, chloracne, acne in 
neonates and infants and late onset, persistent acne, sometimes associated with 
genetic or iatrogenic endocrinopathies. The current guideline do not lend themselves 
to comprehensive management of all of these variants. 
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2 Assessment, comparability of treatment outcomes 
Finlay/ Layton 
2.1 Acne grading 
Acne can be largely assessed from two perspectives: objective disease activity 
(based on measurement of visible signs) and quality of life impact. There are other 
aspects of measurement, such as sebum excretion rate, colonisation by 
Propionibacterium acnes (P. acnes), scarring development or economic impact. 
Accurately assessing outcomes from therapy is notoriously difficult in acne [8]. Many 
different approaches have been adopted but very few are validated. The inconsistent 
application of a standard method for assessing acne severity makes it very difficult to 
challenge interpretation of results from interventional studies. There are detailed 
reviews and reflections on this subject by Lehmann et al. [9], Barratt et al. [10], 
Witkowski et al. [11], Thiboutot et al. [12], Gollnick et al. [13] and Tan et al. [14]. 
Proper lighting, appropriate patient positioning and prior facial skin preparation 
(gentle shaving for men, removal of make-up for women) are helpful in facilitating 
accurate assessment. Palpation in addition to visual inspection may also help define 
lesions more accurately. 
Mechanisms to assess acne lesions using digital multimodal imaging are being 
evaluated but have not yet been accepted or validated for use in clinical practice [15]. 
Patient reported outcomes are now also being considered as an important part of 
overall assessment [16]. However, the most frequently used outcome measures to 
assess acne involve grading or counting. These evaluations can be further divided 
into: (i) an evaluation according to the predominant lesion type; (ii) evaluations of 
separate individual lesions; (iii) overall or ‘global’ assessment. Lesion counts are 
essential for clinical trials as they offer a reliability not evident in global assessment, 
however counting remains impractical for use in the day-to-day clinic [17] and does 
not accurately reflect overall severity [18]. In systematic reviews, global grading has 
been used as an efficacy measure in up to 62% of acne trials [9, 10] and the USA 
Food and Drug Administration (FDA) has mandated global grading as one of two 
efficacy measures in which superiority must be demonstrated for approval of acne 
therapies [18]. However, no one global system has been established as a standard: 
some utilize quantitative measures e. g. lesion counts and numeric ranges and 
others are based on qualitative descriptions. 
2.1.1 Acne grading systems 
2.1.1.1 Sign-based methods 
Despite a range of methods being used to measure acne in the 1960’s and 1970’s, it 
was the Leeds technique [5] that dominated acne measurement for the next two 
decades. The Leeds technique included two methods; the grading technique and the 
counting technique. The grading technique allocated patients a grade from 0 to 10, 
with seven subgroups between 0 and 2. Photographic guides illustrating each grade 
are given, but the importance of also palpating lesions is stressed. The experience 
on which this system was based stemmed from the pre-isotretinoin era, and acne of 
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the severity described by grades above 2 is now rarely seen. The counting technique 
involves the direct counting of non-inflamed and inflamed lesions, including 
superficial papules and pustules, deep inflamed lesions and macules. The revised 
Leeds acne grading system [19] includes numerical grading systems for the back and 
chest as well as for the face. 
The Echelle de Cotation des Lesions d’Acne (ECLA) or “Acne Lesion Score Scale” 
system has demonstrated good reliability [20]. However, ECLA scores do not 
correlate with quality of life scores and the use of both disease and quality of life 
scores is suggested [21]. 
Persisting hyperpigmentation after active acne has settled is of great concern to 
many patients. An instrument to measure this has been described, the post acne 
hyperpigmentation index (PAHPI) [22]. 
2.1.1.2 Global assessment techniques 
Global assessment scales incorporate the entirety of the clinical presentation into a 
single category of severity. Each category is defined by either photographs with a 
corresponding numeric scale or by descriptive text. Grading is a subjective task, 
based on observing dominant lesions, evaluating the presence or absence of 
inflammation, which is particularly difficult to capture, and estimating the extent of 
involvement. Global methods are much more practically suited to clinical practice. In 
clinical investigations, they should be combined with lesion counts as a co-primary 
endpoint of efficacy [23]. A simple photographic standard-based grading method 
using a 0-8 scale has been successfully employed in several clinical trials [24]. 
A very simple classification of acne severity was described in the 2003 report from 
the Global Alliance for better outcome of acne treatment [13]. This basic classification 
was designed to be used in a routine clinic, and its purpose was to map treatment 
advice onto common clinical presentations. For each acne descriptor a first-choice 
therapy is advised, with alternatives for females and maintenance therapy. There are 
five simple descriptors: mild comedonal, mild papulopustular, moderate 
papulopustular, moderate nodular, and severe nodular/ conglobate. A series of eight 
photographs span and overlap these five descriptors. Different facial views and 
different magnifications are used, reducing the comparability of the images. 
In 2005, the FDA proposed an investigator global assessment (IGA) that represented 
a static quantitative evaluation of overall acne severity. To accomplish this, they 
devised an ordinal scale with five severity grades, each defined by distinct and 
clinically relevant morphological descriptions that they hoped would minimise inter-
observer variability. Indeed, the more detailed descriptive text has resulted in this 
system being considered to provide even greater reliability than previous global 
assessments [18]. 
The Comprehensive Acne Severity System (CASS), was developed by extending a 
pre-existing 6-category facial IGA scale, ranging from clear through to very severe 
grading, to include the chest and back [25]. This has been validated and provides a 
global system that includes a restricted number of categories to allow for a practical 
and comprehensive approach when assessing treatment outcomes. 
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In order to give treatment recommendations based on disease activity, the EU 
Guideline group has considered how best to classify acne patients. It has used the 
following simple clinical classification: 
1. Comedonal acne 
2. Mild - moderate papulopustular acne 
3. Severe papulopustular acne, moderate nodular acne 
4. Severe nodular acne, conglobate acne 
Other already existing systems are very difficult to compare with one another. The 
group has tried to map the existing systems to the guidelines’ clinical classification. 
However, in many cases the systems do not include corresponding categories and 
often it has to be considered an approximated attempt rather than a precise mapping 
(Table 1). 
Publication Comedonal 
acne 
Mild-
moderate 
papulo-
pustular acne 
Severe 
papulopustular 
acne, 
moderate 
nodular acne 
Severe nodular 
acne, conglobate 
acne 
Pillsbury 1956 [26] - 1 - 4 2 - 4 2 - 4 
Kligman 1976 [27] 1 = < 10 
2 = 10-25 
3 = > 25-50 
4 = > 50 
(facial 
comedones) 
- - - 
Michaelsson 1977 
[28] 
- 0 - 30 20 - 30 20 - >30 
Cook 1979 [24] 0 - 1 2 - 4 6 8 
Wilson 1980 [29] 0 2 - 4 6 - 8 8 
Allen 1982 [30] 0 - 2 2 - 6 6 8 
Burke (Leeds) 
1984 [5] 
0.5 0.75 - 2 2 - 3 3 - 8 
Pochi 1991 [23] Mild Mild/moderate Moderate Severe 
O’Brien (Leeds) 
1998 (face) [19] 
1 - 3 4 - 7 8 - 10 11 - 12, 
nodulocystic 
Dreno 1999 [20] F1R1 - 5 F1Is1 - 4 F1Is4 - 5, 
F1Ip 1 - 4 
F1Ip 4 - 5 
Lehmann 2002 [9] Mild Mild/moderate Severe Severe 
Gollnick 2003 [13] Mild 
comedonal 
Mild papular-
pustular, 
moderate 
papular-
pustular 
Moderate 
nodular 
Severe nodular/ 
conglobate 
FDA’s IGA for 
acne vulgaris 
(2005) [18] 
1 Almost 
clear: rare 
NIL with no 
more than 1 
2 Mild: some 
NIL but no 
more than a 
few papule/ 
3 Moderate: 
many NIL, some 
IL no more than 
1 nodule 
4 Severe: up to 
many non-
inflammatory and 
inflammatory 
Field Code Changed
Formatted: Spanish (Spain)
Field Code Changed
Formatted: Spanish (Spain)
Formatted: Spanish (Spain)
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papule pustule lesions, but no 
more than a few 
nodular lesions 
Del Rosso 2007 
[31] 
- Mild  Moderate  Severe 
Tan 2007 [25] - Mild: 0-5 
papules- 
pustules 
Moderate: 6-20 
papules - 
pustules 
Severe: 21-50 
papules - pustules, 
Very severe: >50 IL 
Severe 
Hayashi 2008 [32] - Mild 0-5 
Papules and 
pustules 
Moderate 6-20 
Papules and 
pustules  
Severe 21-50 
papules and 
pustules 
>50 very severe 
Layton 2010 [33] - Mild  Moderate Severe 
Dreno 2011 [34] 0-5 Mild 
1-2 
Moderate 
2-4 
Severe 
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Table 1 Comparison of different acne assessment scales. This is an attempt to approximately map the 
various published acne classifications to the simple four group classification used in this guideline. 
2.1.1.3 Quality of life methods 
The use of Quality of Life (QoL) measures captures the impact of acne as well as the 
impact of treatment on the patient’s life and as a result supports identification of 
those vulnerable to psychological complications. Adopting a QoL measure as an 
integral part of acne management is recommended. In order for quality of life 
measures to be used more frequently in routine clinical work, they need to be easy to 
use, the scores need to be meaningful, and they need to be readily accessible. It is 
possible to measure the impact of acne on quality of life using several 
questionnaires. There are acne-specific, dermatology-specific and generic measures, 
which can be used across all diseases. 
Acne specific measures include the “Assessments of the Psychological and Social 
Effects of Acne” (APSEA) questionnaire [35, 36], the Cardiff Acne Disability Index 
[37, 38] the Acne Quality of Life Scale (AQOL) [39], the Acne-specific Quality of Life 
Questionnaire (Acne-QoL) [40] and the short version of this, the Acne-Q4 [41]. A 
recent novel patient reported outcome measure, the Acne Symptom and Impact 
Scale (ASIS) seeks to capture both symptoms and impacts of facial acne [42, 43]. 
Dermatology specific measures used in acne include the Dermatology Life Quality 
Index (DLQI) [44-46], the Children’s Dermatology Life Quality Index (CDLQI) [47] and 
Skindex-29, -16 [48]. Generic measures used in acne include the SF-36 (Mallon) and 
the General Health Questionnaire [49]. 
In addition it is possible to measure the secondary impact of acne on the lives of 
partners and other family members, using a dermatology specific measure, the 
Family Dermatology Life Quality Index [50] and a generic measure, the Family 
Reported Outcome Measure (FROM-16) [51]. 
Acne also affects functional abilities. Patients are prone to embarrassment and social 
withdrawal, depression, anxiety and anger. The combined use of QoL and 
psychosocial questionnaires is essential to adequately understand just how severely 
Formatted: English (United Kingdom)
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the disease is affecting a patient, and can aid in assessing the efficacy of therapy 
and justifying clinical decisions. In patients with a severe impact on their quality of 
life, a more aggressive therapy may be justified. 
2.2 Prognostic factors that should influence treatment choice 
2.2.1 Prognostic factors of disease severity 
A number of prognostic factors relating to more severe disease should be considered 
when assessing and managing acne. These are outlined and evidenced in review 
papers published by Holland and Jeremy 2005 [52] and Dreno et al. 2006 [53] and 
include family history, course of inflammation, persistent or late-onset disease, 
hyperseborrhoea, androgenic triggers, truncal acne and/ or psychological sequelae. 
Previous infantile acne may also correlate with resurgence of acne at puberty and 
early age of onset with mid-facial comedones, early and more severe seborrhoea 
and earlier presentation relative to the menarche are all factors that should alert the 
clinician to increased likelihood of more severe acne. 
2.2.2 The influence of the assessment of scarring/ potential for scarring 
on disease management 
Scarring usually follows deep-seated inflammatory lesions, but may also occur as a 
result of more superficial inflamed lesions in scar-prone patients. Acne scarring, 
albeit mild, has been identified in up to 95 % of patients attending a dermatology 
clinic [54]. Scars may show increased collagen (hypertrophic and keloid scars) or be 
associated with collagen loss which is a more frequent consequence of inflammatory 
acne [55]. The duration of inflammation relates to scar production hence a delay in 
appropriate management is more likely to result in significant scarring [25, 54]. 
Acne scarring should also be included in the assessment of acne severity. Scars can 
produce significant disfigurement and psychosocial impairment in their own right. The 
difficulty in evaluation of acne scars is manifold and clinical assessment of scars 
demonstrates significant variation between assessors [56]. Several different systems 
have been described to evaluate acne scars (see Table 2). Other techniques have 
been employed in an attempt to quantify scarring at specified time points in relation 
to treatment. These include ultrasound [57] surface profilometry using silicone 
imprints [58], standardized photography [59], and three dimensional in vivo 
microtopography measurements [60]. 
However, to date no single validated method to evaluate the extent or volume 
deficiency of acne scars has been uniformly adopted for use in routine clinical 
practice. 
The presence of scarring should support aggressive management and therapy 
should be commenced early in the disease process. 
Acne Scar System Severity Scheme Regional Relevance 
Leeds [54] Numeric (Maximum 30 for each 
region) 
Face, chest and back 
Echelle d’Evaluation Clinique des 
Cicatrices d’Acne [61] 
Numeric (maximum 540) Face 
Deleted: 0
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Qualitative Global Acne Scarring 
Grading System [62] 
Four descriptive grades Face, chest and back 
Quantitative Global Acne 
Scarring Grading System [63] 
Numeric (maximum 84) Face 
Patient and Observer Scar 
Assessment Scale (POSAS) [64] 
Numeric (maximum 50 
observer/maximum 60 patient) 
Face 
New evidence-based facial acne 
scar evaluation tool (FASET) to 
assess atrophic scars [65] 
Global, Dispersion, Numeric Face 
Table 2 Acne scare severity grading systems 
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3 Epidemiology and pathophysiology 
3.1 Epidemiology 
Degitz/ Ochsendorf 
Acne is regarded as one of the most frequent skin diseases. Epidemiologic studies in 
Western industrialized countries estimated the prevalence of acne in adolescents to 
be between 50% and 95%. If mild manifestations were excluded and only moderate 
or severe manifestations were considered, the frequency was still 20% - 35% [66-69]. 
Acne is a disease primarily of adolescence. It is triggered in children by the initiation 
of androgen production by the adrenal glands and gonads. It may begin as early as 
age 7-9 [70] and usually subsides after the end of growth. However, to some degree, 
acne may persist beyond teen age in a significant proportion of individuals [71]. Even 
after the disease has ended, acne scars and hyper- or hypopigmentation are not 
uncommon permanent negative outcomes [12]. Genetic factors have been 
recognized [72]. There is a high concordance among identical twins, and there is also 
a tendency towards severe acne in patients with a positive family history [73]. 
Multiple genes are probably involved in acne predisposition, among others 
cytochrome P450-1A1 and several enzymes involved in androgen metabolism [74, 
75]. A genome-wide association study revealed a role for the dysregulation of TGFβ-
mediated signalling in the susceptibility to acne [76]. Environmental factors also 
appear to be of relevance for acne prevalence. Of note, diet has recently gained 
attention. Populations with a natural lifestyle do not develop acne [77], and 
epidemiologic [78] and investigative studies [79] correlate acne with Western diet. 
3.2 Pathophysiology 
Dréno/ Gollnick 
Acne is an androgen-dependent disorder of pilosebaceous follicles (or pilosebaceous 
unit). There are four primary pathogenic factors, which interact to produce acne 
lesions: 1) sebum production by the sebaceous gland, 2) alteration in the follicular 
keratinization process, 3) Propionibacterium acnes follicular colonization, and 4) 
release of inflammatory mediators. 
Patients with seborrhoea and acne have a significantly greater number of lobules per 
gland compared with unaffected individuals (the so-called genetically prone 
“Anlage”). Inflammatory responses occur prior to the hyperproliferation of 
keratinocytes. Interleukin-1α up-regulation contributes to the development of 
comedones independent of the colonization with P. acnes. A relative linoleic acid 
deficiency has also been described. 
Sebaceous lipids are regulated by peroxisome proliferator-activated receptors which 
act in concert with retinoid X receptors to regulate epidermal growth and 
differentiation as well as lipid metabolism. Sterol response element binding proteins 
mediate the increase in sebaceous lipid formation induced by insulin-like growth 
factor-1. Substance P receptors, neuropeptidases, α-melanocyte stimulating 
hormone, insulin-like growth factor (IGF)-1R and corticotrophin-releasing hormone 
(CRH)-R1 are also involved in regulating sebocyte activity as are the ectopeptidases, 
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such as dipeptidylpeptidase IV and animopeptidase N. The sebaceous gland also 
acts as an endocrine organ in response to changes in androgens and other 
hormones. DHEA-S is a stimulator of IL-2 driven T-cells and, therefore, driving the 
inflammatory process. [80] Oxidized squalene can stimulate hyperproliferative 
behaviour of keratinocytes, and lipoperoxides produce leukotriene B4, a powerful 
chemoattractant. 
Microcomedones, macules and further developed visible lesions of acne produces 
chemotactic factors and promote the synthesis of tumour necrosis factor- and 
interleukin-1. Another cytokine, IL-17 has been identified as potentially playing an 
important role in addition of IL-1β in acne [81]. Cytokine induction by P. acnes occurs 
through Toll-like receptor (TLR) 2 activation via activation of nuclear factor-B and 
activator protein 1 (AP-1) transcription factor. P acnes activates also Protease 
activated Receptor (PAR) 2. [82] Both TLR and PAR belongs to the innate immunity 
and play a crucial role in the modulation and duration of inflammation of acne lesions 
in association with the antimicrobial peptides. [83] Activation of AP-1 induces matrix 
metalloproteinase genes, the products of which degrade and alter the dermal matrix 
and could be a central factor in the development of acne scars. Recent data indicate 
that the phylotypes of P acnes are different comparing healthy controls and acne 
patients and in addition that different phylotypes of P acnes have different pro 
inflammatory activities, modulating differently the innate immunity. [84-87] P acnes as 
the therapeutic target has become questionable after studies showing that not all 
follicles are P acnes colonized, the number of P acnes are not correlating with the 
intensity of inflammatory reactions and course of the disease, but certain strains are 
correlating with the severity grade and course of acne. [88] Recently, it could be 
shown that the inflammasome is activated and IL-1ß is activated [89]. Furthermore, 
new findings on the role of growth factors such as IGF-1 in the regulation of the 
sebocytes have demonstrated that transcriptional factors such as FOX-O1 can 
interact with PPAR gamma and sebocyte differentiation and proliferation and may 
give some hint to a possible role of diets in the daily practice of acne patients. 
However, it could be shown for the first time that those growth factors also upregulate 
TLR 2 and 4. This means that not only P acnes is a key for upregulating TLR [90]. 
The improved understanding of acne development on a molecular level suggests that 
acne is a disease that involves both innate and adaptive immune systems with a 
predominant role for innate immunity in the regulation of inflammatory events. 
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4 Methods - Assessment of evidence 
(For further details please see the methods report at www.acne-guideline.com.) 
Nast/ Rosumeck 
Many different grading systems for assessing the quality of evidence are available in 
the field of guideline development. For this guideline, the authors used the grading 
system adopted from the European Psoriasis Guideline (version 2010) [91, 92], 
already used in the previous acne guideline 2011 [93, 94]. 
4.1 Grade of evidence (quality of individual trial) 
The available literature was evaluated with respect to the methodological quality of 
each single trial. A grade of evidence was given to every individual trial included: 
A Randomized, double-blind clinical trial of high quality (e. g. sample-size 
calculation, flow chart of patient inclusion, intention-to-treat [ITT] analysis, 
sufficient sample size) 
 
B Randomized clinical trial of lesser quality (e. g. only single-blind, no ITT) 
 
C Comparative trial with severe methodological limitations (e. g. not blinded, 
very small sample size) 
4.2 Level of evidence (quality of body of evidence to answer a 
specific question) 
When looking at a specific question (e. g. efficacy of BPO relative to adapalene) the 
available evidence was summarized by aligning a level of evidence (LE), as our 
criteria were combined with the definition of GRADE [95] as used in the 2011 acne 
guideline version: 
1 Further research is very unlikely to change our confidence in the 
estimate of effect. 
At least two trials are available that were assigned a grade of evidence A and 
the results are predominantly consistent with the results of additional grade B 
or C studies. 
2 Further research is likely to have an important impact on our confidence 
in the estimate of effect and may change the estimate. 
At least three trials are available that were assigned a grade of evidence B and 
the results are predominantly consistent with respect to additional grade C 
trials. 
3 Further research is very likely to have an important impact on our 
confidence in the estimate of effect and is likely to change the estimate. 
Conflicting evidence or limited amount of trials, mostly with a grade of evidence 
of B or C. 
4 Any estimate of effect is very uncertain. 
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Little or no systematic empirical evidence; included trials are extremely limited 
in number and/ or quality. 
4.3 Consensus process 
All recommendations were agreed on in an online-telephone consensus conference 
using a formal and structured consensus methodology. The consensus conference 
was moderated by PD Dr. med. Alexander Nast, who is a certified moderator for the 
German Association of Scientific Medical Societies (AWMF). All nominated experts 
were entitled to vote in the consensus conference. 
In order to weight the different recommendations, the group assigned a “strength of 
recommendation” grade (see box below). The strength of recommendation 
considered all aspects of the treatment decision, such as efficacy, safety, patient 
preference, and the reliability of the existing body of evidence (level of evidence). 
Strength of recommendation 
 
In order to grade the recommendation a “standardized guideline“ language was used: 
 
1) is strongly recommended 
2) can be recommended 
3) can be considered 
4) is not recommended 
5) may not be used under any circumstances 
6) a recommendation for or against treatment X cannot be made at the present time. 
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5 Induction therapy 
Summary of therapeutic recommendations 1 for induction therapy 
Recommendations are based on available evidence and expert consensus. Available 
evidence and expert voting lead to classification of strength of recommendation. 
 Comedonal 
acne 3 
Mild to moderate 
papulopustular acne 
Severe 
papulopustular/ 
moderate nodular 
acne 
Severe nodular/ 
conglobate acne 12 
High 
strength of 
recommen-
dation 
- 
Adapalene + BPO (f.c.) 
or 
BPO + Clindamycin 
(f.c.) 5 
Isotretinoin Isotretinoin 
Medium 
strength of 
recommen-
dation 
Topical 
retinoid 4 
Azelaic acid 
or 
BPO 
or 
Topical Retinoid 4 
or 
Topical Clindamycin + 
Tretinoin (f.c.) 5 
or 
Systemic Antibiotic 5,6,7 
+ Adapalene 8 
Systemic Antibiotic 5,7 
+ Adapalene 8 
or 
Systemic Antibiotic 5,7 
+ Azelaic acid 9 
or 
Systemic Antibiotic 5,7 
+ Adapalene + BPO 
(f.c.) 
Systemic Antibiotic 
5,7 + Azelaic Acid 
or 
Systemic Antibiotic 
5,7 + Adapalene + 
BPO (f.c.) 
Low 
strength of 
recommen-
dation 
Azelaic acid 
or 
BPO 
Blue Light 
or 
Oral Zinc 
or 
Systemic Antibiotic 5,6,7 
+ Azelaic Acid 9 
or 
Systemic Antibiotic 5,6,7 
+ Adapalene + BPO 
(f.c.) 10 
or 
Systemic Antibiotic 5,6,7 
+ BPO 11 
or 
Topical Erythromycin + 
Isotretinoin (f.c.) 5 
or 
Topical Erythromycin + 
Tretinoin (f.c.) 5 
Systemic Antibiotic 5,7 
+ BPO 11 
Systemic Antibiotic 
5,7 + Adapalene 8,10 
or 
Systemic Antibiotics 
5,7 + BPO 10 
Alternatives 
for females 
2
 
- - 
Hormonal 
Antiandrogens + 
Systemic Antibiotic 5,7 
+ Topicals (apart 
from antibiotics) 
or 
Hormonal 
Antiandrogens + 
Topical Treatment 
Hormonal 
Antiandrogens + 
Systemic Antibiotic 
5,7
 + Topicals (apart 
from antibiotics) 
or 
Hormonal 
Antiandrogens + 
Topical Treatment 
1
 Limitations can apply that may necessitate the use of a treatment with a lower strength of recommendation 
as a first line therapy (e. g. financial resources/ reimbursement limitations, legal restrictions, availability, drug 
licensing). 
2
 low strength of recommendation 
3
 The recommendation for comedonal treatment passed with vote of 60% agreement only,  see chapter 5.1 for 
more details. 
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4
 adapalene to be preferred over tretinoin/ isotretinoin (see Chapter 5.4.1) 
5
 Prescribers of antibiotics should be aware of the potential risk of the development of antibiotic resistances . 
6
 In case of more widespread disease/ moderate severity, initiation of a systemic treatment can be 
recommended. 
7
 doxycycline and lymecycline (see Chapter 5.4.2), limited to a treatment period of three months 
8
 only studies found on systemic AB + adapalene; topical isotretinoin and tretinoin can be considered for 
combination treatment based on expert opinion 
9
 indirect evidence from nodular and conglobate acne and expert opinion 
10
 indirect evidence from severe papulopustular acne 
11 indirect evidence from a study also including chlorhexidin, recommendation additionally based on expert 
opinion 
12
 systemic treatment with corticosteroids can be considered 
13   the f.c. of clindamycin/tretinoin shows comparable efficacy and safety to the f.c. BPO/clindamycin, 
downgrading to a medium strength of recommendation was done based on concerns with respect to the 
development of antibiotic resistance 
f.c. fixed combination 
5.1 Treatment of comedonal acne 
5.1.1 Recommendations for comedonal acne 
High strength of recommendation 
None 
 
Medium strength of recommendation 
Topical retinoids 2 can be recommended for the treatment of comedonal acne. 
 
Low strength of recommendation 
Azelaic acid can be considered for the treatment of comedonal acne. 
BPO can be considered for the treatment of comedonal acne. 
 
Open recommendation 
A recommendation for or against treatment of comedonal acne with visible light as 
monotherapy, lasers with visible wavelengths and lasers with infrared wavelengths, 
with intense pulsed light (IPL) and photodynamic therapy (PDT) cannot be made at 
the present time. 
 
Negative recommendation 
Topical antibiotics are not recommended for the treatment of comedonal acne. 
Hormonal antiandrogens, systemic antibiotics and/ or systemic isotretinoin are not 
recommended for the treatment of comedonal acne. 
Artificial ultraviolet (UV) radiation is not recommended for the treatment of 
comedonal acne. 
1
 Limitations can apply that may necessitate the use of a treatment with a lower strength of recommendation 
as a first line therapy (e. g. financial resources/ reimbursement limitations, legal restrictions, availability, drug 
licensing). 
2
 adapalene to be preferred over tretinoin/ isotretinoin (see Chapter 5.4.1) 
5.1.2 Reasoning 
General comment: Only one trial looks specifically at patients with comedonal acne. 
As a source of indirect evidence, trials including patients with papulopustular acne 
were used and the percentage in the reduction of non-inflammatory lesions was 
considered as the relevant outcome parameter. Because of the general lack of direct 
evidence for the treatment of comedonal acne, the strength of recommendation was 
1 
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downgraded for all considered treatment options, starting with medium strength of 
recommendation as a maximum. 
Due to the usually mild to moderate severity of comedonal acne, generally a topical 
therapy is recommended. 
The best efficacy was shown for topical retinoids, BPO and azelaic acid. 
The tolerability of topical retinoids and BPO is comparable; there is a trend towards 
azelaic acid having a better safety/ tolerability profile than BPO and a comparable 
profile to adapalene (indirect evidence, see Table 11). 
The fixed dose combination of adapalene with BPO shows a trend towards better 
efficacy against non-inflammatory lesions (NIL) when compared to BPO and a 
comparable efficacy when compared to adapalene (see Table 4). However, there is 
also a trend towards inferiority of the fixed combination with respect to the safety/ 
tolerability profile (indirect evidence, see Table 12). 
The fixed dose combinations of clindamycin with BPO showed a trend towards better 
efficacy against NIL versus clindamycin and comparable efficacy versus BPO (see 
Table 5). With respect to the safety/ tolerability profile, the combination is comparable 
to its single components (indirect evidence, see Table 12). 
Few and only indirect data on patient preference are available. They indicate patient 
preference for adapalene over other topical retinoids. 
Additional pathophysiological considerations favour the use of topical retinoids 
(reduction of microcomedones). 
5.1.2.1 Efficacy 
See Table 3 to Table 5 for summary of efficacy data. Please see methods report for 
explanation of assessment strategy. 
Table 3 Efficacy: Comedonal acne - top. therapy vs. vehicle/ top. therapy 
 Vehicle (v) Azelaic acid (aa) Adapalene (a) Isotretinoin (i) Tretinoin (t) 
BPO BPO > v LE 1 
BPO > aa 
LE 4 
BPO = a 
LE 1 
BPO = i 
LE 3 
t ≥ BPO 
LE 4* 
Azelaic acid 
(aa) 
aa > v 
LE 1 X 
a > aa 
LE 4 ne 
t > aa 
LE 4 
Adapalene 
(a) 
a > v 
LE 1 X X 
a = i 
LE 4 
a = t 
LE 1** 
Isotretinoin 
(i) 
i > v 
LE 1 X X X 
i > t 
LE 4 
Tretinoin (t) t > v LE 1 X X X X 
LE=level of evidence; ne=no evidence; top.=topical 
* BPO 5% = tretinoin 0.1% (LE 4); tretinoin 0.025% > BPO 5% (LE 4)  
** adapalene 0.1% = tretinoin 0.025% (LE 1); tretinoin 0.05% ≥ adapalene 0.1% (LE 4); TMG 0.1% ≥ 
adapalene 0.1% (LE 4) 
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Table 4 Efficacy: Comedonal acne - top. antibiotics vs. vehicle/ BPO/ azelaic acid/ top. 
Retinoids  
 Vehicle (v) BPO Azelaic acid (aa) 
Adapalene 
(a) 
Isotretinoin 
(i) 
Tretinoin 
(t) 
Clindamycin 
(c) 
c > v 
LE 2 
BPO ≥ c 
LE 1 
aa ≥ c 
LE 4* ne ne 
t = c 
LE 3 
Erythromycin 
(e) 
e ≥ v 
LE 1 ne 
aa = e 
LE 4 ne 
e = i 
LE 3 ne 
Nadifloxacin 
(n) 
n > v 
LE 4 ne ne ne ne ne 
Tetracycline 
(t) ne 
BPO > t 
LE 3 ne ne ne ne 
LE=level of evidence; ne=no evidence; top.=topical 
* azelaic acid 15% > clindamycin 1% (LE 4); clindamycin 1% = azelaic acid 5% (LE 4) 
Table 5 Efficacy: Comedonal acne - top. combination therapy vs. top. therapy/ combinations 
 
Vehicle 
(v) BPO 
Adapa-
lene 
(a) 
Iso-
treti-
noin 
(i) 
Treti-
noin 
(t) 
Clin-
da-
mycin 
(c) 
Ery-
thro-
mycin 
(e) 
Adapa-
lene-
BPO (a-
BPO) 
BPO-
clinda-
mycin 
(BPO-c) 
Clinda-
mycin- 
tretino-
in (ct) 
Adapale
ne-BPO 
(a-BPO) 
a-BPO 
> v 
LE 1 
a-BPO 
> BPO 
LE 3 
a-BPO 
= a 
LE 3 
ne ne ne ne X X ne 
BPO-
clinda-
mycin 
(BPO-c) 
BPO-c 
> v 
LE 1 
BPO-c 
= BPO 
LE 1 
a = 
BPO-c 
LE 3 
ne ne 
BPO-
c > c 
LE 1 
ne 
BPO-c 
= a-
BPO 
LE 4 
X 
BPO-c 
= ct 
LE 4 
Clinda-
mycin- 
tretinoin 
(ct) 
ct > v 
LE 1 ne ne ne 
ct = t 
LE 1 
ct > c 
LE 4 ne ne X X 
Clinda-
mycin-
zinc (cz) 
ne ne ne ne ne 
cz = c 
LE 3 ne ne ne ne 
Erythro-
mycin- 
isotreti-
noin (ei) 
ei > v 
LE 3 ne ne 
ei = i 
LE 3 ne ne 
ei = e 
LE 3 ne ne ne 
Erythro-
mycin- 
tretinoin 
(et) 
ne ne ne ne ne ne ne ne ne ne 
Erythro-
mycin-
zinc (ez) 
ez > v 
LE 1 ne ne ne ne 
ez >c 
LE 4 
ez ≥ e 
LE 3 ne 
BPO-c > 
ez 
LE 4 
ne 
LE=level of evidence; ne=no evidence; top.=topical 
 
Light sources 
Although in the literature search for the first version of this guideline, there were 
some studies for the treatment of NIL with laser and light sources, no clear 
recommendations could be drawn. The published evidence was very scarce.  
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5.1.2.2 Safety/ tolerability 
Only one trial looked specifically at comedonal acne. It showed a superior safety/ 
tolerability profile for azelaic acid compared with tretinoin (LE 4) [96]. 
As a source of further indirect evidence, trials in patients with papulopustular acne 
were considered to evaluate the safety and tolerability profile of the included 
treatments. For a summary of the data, see Chapter 5.2.3.2. 
5.1.2.3 Patient preference 
Based on a systematic review by Dressler et al. [97] there is only indirect evidence 
from trials including patients with mild to moderate papulopustular acne, see chapter 
5.2.3.3. 
5.1.2.4 Other considerations 
Animal experiments, in the rhino mouse model in particular, have shown for decades 
that retinoids have a strong anti-comedonal efficacy. Clinical trials on the 
microcomedo, the natural precursor of comedones, have shown that retinoids 
significantly reduce microcomedo counts. In addition, in vitro data provide 
pathophysiological support for the use of topical retinoids for comedonal acne [98, 
99].  
5.2 Treatment of papulopustular acne 
5.2.1 Recommendations for mild to moderate papulopustular acne 1 
High strength of recommendation 
The fixed-dose combination adapalene and BPO is strongly recommended for the 
treatment of mild to moderate papulopustular acne. 
The fixed-dose combination BPO and clindamycin 2 is strongly recommended for the 
treatment of mild to moderate papulopustular acne. 
 
Medium strength of recommendation 
Azelaic acid can be recommended for the treatment of mild to moderate 
papulopustular acne. 
BPO can be recommended for the treatment of mild to moderate papulopustular 
acne. 
A combination of a systemic antibiotic 2,3,4 with adapalene 5 can be recommended 
for the treatment of moderate papulopustular acne. 
The fixed-dose combination clindamycin and tretinoin 2 can be recommended for the 
treatment of mild to moderate papulopustular acne.10 
Topical retinoids 6 can be recommended for the treatment of mild to moderate 
papulopustular acne. 
 
Low strength of recommendation 
Blue light monotherapy can be considered for the treatment of mild to moderate 
papulopustular acne. 
Oral zinc can be considered for the treatment of mild to moderate papulopustular 
acne. 
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Systemic antibiotic 2,3,4 in combination with azelaic acid 7 can be considered for the 
treatment of mild to moderate papulopustular acne. 
A combination of a systemic antibiotic 2,3,4 with adapalene in fixed-dose combination 
with BPO 8 can be considered for the treatment of moderate papulopustular acne. 
A combination of a systemic antibiotic 2,3,4 with BPO 9 can be considered for the 
treatment of moderate papulopustular acne. 
The fixed-dose combination of erythromycin and isotretinoin 2 can be considered for 
the treatment of mild to moderate papulopustular acne. 
The fixed-dose combination of erythromycin and tretinoin 2 can be considered for 
the treatment of mild to moderate papulopustular acne. 
 
Open recommendation 
Due to a lack of sufficient evidence, a recommendation for or against treatment of 
mild to moderate papulopustular acne with red light, IPL, Laser or PDT cannot be 
made at the present time. 
 
Negative recommendation 
Topical antibiotics as monotherapy are not recommended for the treatment of mild 
to moderate papulopustular acne. 
Artificial UV radiation is not recommended for the treatment of mild to moderate 
papulopustular acne. 
The fixed-dose combination of erythromycin and zinc is not recommended for the 
treatment of mild to moderate papulopustular acne. 
Systemic therapy with anti-androgens, antibiotics, and/ or isotretinoin is not 
recommended for the treatment of mild to moderate papulopustular acne. 
1
 Limitations can apply that may necessitate the use of a treatment with a lower strength of recommendation 
as a first line therapy (e. g. financial resources/ reimbursement limit, legal restrictions, availability, drug 
licensing). 
2
 Prescribers of antibiotics should be aware of the potential risk of the development of antibiotic resistances . 
3
 doxycycline and lymecycline (see Chapter 5.4.2), limited to a treatment period of three months 
4
 In case of more widespread disease/ moderate severity, initiation of a systemic treatment can be 
recommended. 
5
 only studies found on systemic AB + adapalene; isotretinoin and tretinoin can be considered for combination 
treatment based on expert opinion  
6
 adapalene to be preferred over tretinoin/ isotretinoin (see Chapter 5.4.1) 
7
 indirect evidence from nodular and conglobate acne and expert opinion 
8
 indirect evidence from severe papularpustular acne 
9 indirect evidence from a study also including chlorhexidin, recommendation additionally based on expert 
opinion 
10   the f.c. of clindamycin/tretinoin shows comparable efficacy and safety to the f.c. BPO/clindamycin, 
downgrading to a medium strength of recommendation was done based on concerns with respect to the 
development of antibiotic resistance 
5.2.2 Recommendations for severe papulopustular/ moderate nodular 
acne 1  
High strength of recommendation 
Oral isotretinoin monotherapy is strongly recommended for the treatment of severe 
papulopustular/ moderate nodular acne acne. 
 
Medium strength of recommendation 
Systemic antibiotics 2,3 in combination with adapalene 4, with the fixed-dose 
combination of adapalene and BPO, or in combination with azelaic acid 5 can be 
recommended for the treatment of severe papulopustular/ moderate nodular acne. 
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Low strength of recommendation 
Systemic antibiotics 2,3 in combination with BPO 5 can be considered for the 
treatment of severe papulopustular/ moderate nodular acne. 
For females: Hormonal antiandrogens in combination with systemic antibiotic 2,3 and 
topicals (apart from antibiotics) can be considered for the treatment of severe 
papulopustular/ moderate nodular acne. 
For females: Hormonal antiandrogens in combination with a topical treatment can be 
considered for the treatment of severe papulopustular/ moderate nodular acne. 
 
Open recommendation 
Due to a lack of sufficient evidence, a recommendation for or against treatment of 
severe papulopustular/ moderate nodular acne with red light, IPL, Laser or PDT 
cannot be made at the present time. 
Although PDT is effective in the treatment of severe papulopustular/ moderate 
nodular acne, a recommendation for or against its use cannot be made at the 
present time due to a lack of standard treatment regimens that ensure a favourable 
profile of acute adverse reaction. 
 
Negative recommendation 
Single or combined topical monotherapy is not recommended for the treatment of 
severe papulopustular/ moderate nodular acne. 
Oral antibiotics as monotherapy are not recommended for the treatment of severe 
papulopustular/ moderate nodular acne. 
Oral anti-androgens as monotherapy are not recommended for the treatment of 
severe papulopustular/ moderate nodular acne. 
Visible light as monotherapy is not recommended for the treatment of severe 
papulopustular/ moderate nodular acne. 
Artificial UV radiation sources are not recommended as a treatment of severe 
papulopustular/ moderate nodular acne. 
1
 Limitations can apply that may necessitate the use of a treatment with a lower strength of recommendation 
as a first line therapy (e. g. financial resources/ reimbursement limit, legal restrictions, availability, drug 
licensing). 
2
 Prescribers of antibiotics should be aware of the potential risk of the development of  antibiotic resistances. 
3
 doxycycline and lymecycline (see Chapter 5.4.2), limited to a treatment period of three months 
4
 only studies found on systemic AB + adapalene; isotretinoin and tretinoin can be considered for combination 
treatment based on expert opinion  
5
 indirect evidence from nodular and conglobate acne and expert opinion 
6 indirect evidence from a study also including chlorhexidin, recommendation additionally based on expert 
opinion 
5.2.3 Reasoning 
Monotherapy with azelaic acid, BPO or topical retinoids showed superior efficacy 
when compared with vehicle. 
Adapalene, azelaic acid and BPO showed comparable efficacy when compared with 
each other. When comparing the topical retinoids (adapalene, isotretinoin and 
tretinoin) directly against each other, no relevant difference with respect to efficacy 
was seen. Some conflicting evidence to the comparability of the efficacy of the 
treatment options above arises, when looking at the other head to head comparisons 
indicating superiority of BPO over isotretinoin and tretinoin over azelaic acid. 
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With respect to the fixed combinations, BPO/ clindamycin shows superiority over 
both single components. 
The three fixed combinations of adapalene/ BPO, clindamycin/ tretinoin as well as 
erythromycin/ isotretinoin show superiority to one of the components but not to both 
of the components when compared individually. 
Head to head comparisons of the fixed combinations of adapalene/ BPO versus 
BPO/ clindamycin as well as head to head comparisons of clindamycin/ tretinoin 
versus BPO/ clindamycin show comparable efficacy. 
Due to the risk of developing antibiotic resistance, topical monotherapy with 
antibiotics is generally not recommended. The potential risk of developing antibiotic 
resistance was taken into consideration by the expert group. It lead to a medium 
strength of recommendation for the fixed combination of clindamycin/ tretinoin 
despite comparable efficacy and safety when compared to the fix combination of  
BPO/clindamycin. The differentiation between clindamycin/ tretinoin (medium 
strength of recommendation) and erythromycin/ isotretinoin (low strength of 
recommendation) was based on evidence showing the lack of development of 
antibiotic resistance after 16 weeks of treatment with clindamycin/ tretinoin [100] as 
well as indirect evidence on stronger development of antibiotic resistance to 
erythromycin [101] and expert opinion on better follicular penetration and galenic of 
the clindamycin/ tretinoin formulation. 
Monotherapy with azelaic acid, BPO, or topical retinoids showed comparable efficacy 
when compared with each other. 
For severe cases, systemic treatment with isotretinoin is recommended based on the 
very good efficacy seen in clinical practice. 
The available evidence on safety and tolerability is extremely scarce and was 
considered insufficient to be used as a primary basis to formulate treatment 
recommendations. 
The lack of standardized protocols, experience and clinical trial data mean there is 
insufficient evidence to recommend the treatment of papulopustular acne with laser 
and light sources other than blue light. 
Choice of topical versus systemic treatment 
There are limited data comparing topical treatments with a systemic treatment or the 
additional effect of a combination of a topical plus systemic versus topical treatment 
only. Most of the available trials compare a topical antibiotic monotherapy with a 
systemic antibiotic monotherapy. 
Issues of practicability between topical and systemic treatments must also be taken 
into consideration in cases of severe, and often widespread, disease. 
The consensus within the expert group was that most cases of severe papulopustular 
acne or moderate nodular acne, will achieve better efficacy when a systemic 
antibiotic treatment in combination with a topical treatment or if systemic isotretinoin 
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is used. In addition, better adherence and patient satisfaction is anticipated for 
systemic treatments. 
5.2.3.1 Efficacy 
See Table 6 to Table 10 for summary of efficacy data. Please see methods report for 
explanation of assessment strategy. 
Table 6 Efficacy: Papulopustular acne - top. therapy vs. vehicle/ top. therapy 
 Vehicle (v) Azelaic acid (aa) Adapalene (a) Isotretinoin (i) Tretinoin (t) 
BPO BPO > v LE 1 
BPO = aa 
LE 2 
BPO = a 
LE 1 
BPO > i 
LE 3 
conflicting 
LE 4* 
Azelaic acid 
(aa) 
aa > v 
LE 1 X 
aa = a 
LE 4 ne 
t > aa 
LE 4 
Adapalene 
(a) 
a > v 
LE 1** X X 
i = a 
LE 4 
a = t 
LE 2-4*** 
Isotretinoin 
(i) 
i > v 
LE 1 X X X 
i = t 
LE 4 
Tretinoin (t) t > v LE 1 X X X X 
LE=level of evidence; ne=no evidence; top.=topical 
* tretinoin 0.025% > BPO 5% (LE 4); BPO 5% > tretinoin 0.1% (LE 4); BPO 5-10% = tretinoin 0.05% 
(LE 4) 
** adapalene 0.1% > placebo/vehicle (LE 1); adapalene 0.3% > placebo/vehicle (LE 1) 
*** adapalene 0.1% = tretinoin 0.025% (LE 2); tretinoin 0.05% > adapalene 0.1% (LE 4); TMG 0.1% = 
adapalene 0.1% (LE 3) 
Table 7 Efficacy: Papulopustular acne - top. combination therapy vs. top. therapy/ 
combinations 
 
Vehicle 
(v) BPO 
Ada-
palene 
(a) 
Iso-
treti-
noin 
(i) 
Tre-
tino-
in (t) 
Clin-
damy-
cin (c) 
Ery-
thro-
mycin 
(e) 
Adapa-
lene-
BPO (a-
BPO) 
BPO- 
clinda-
mycin 
(c-BPO) 
Clinda-
mycin- 
tretino-
in (ct) 
Adapale-
ne-BPO 
(a-BPO) 
a-BPO 
> v 
LE 1 
a-BPO 
= BPO 
LE 3 
a-BPO 
> a 
LE 1 
ne ne ne ne X X X 
BPO-
clindamy-
cin (BPO-
c) 
BPO-c 
> v 
LE 1 
BPO-c 
> BPO 
LE 4 
BPO-c 
> a 
LE 3 
ne ne 
BPO-
c > c 
LE 1 
ne 
BPO-c 
= a-
BPO 
LE 4* 
X X 
Clinda-
mycin- 
tretinoin 
(ct) 
ct > v 
LE 1 ne ne ne 
ct > t 
LE 1 
ct = c 
LE 2 ne ne 
BPO-c 
= ct 
LE 4 
X 
Clindamy-
cin-zinc 
(cz) 
ne ne ne ne ne 
cz = c 
LE 3 ne ne ne ne 
Erythro-
mycin -
isotretino-
ei > v 
LE 3 ne ne 
ei > i 
LE 3 ne ne 
ei = e 
LE 3 ne ne ne 
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in (ei) 
Erythro-
mycin-
tretinoin 
(et) 
ne ne ne ne ne ne ne ne ne ne 
Erythro-
mycin-
zinc (ez) 
ez > v 
LE 1 ne ne ne ne 
ez > c 
LE 4 
ez ≥ e 
LE 3 ne 
BPO-c 
= ez 
LE 4 
ne 
LE=level of evidence; ne=no evidence; top.=topical 
* clindamycin-BPO = adapalene-BPO after 12 weeks of treatment (LE 4); clindamycin-BPO = 
adapalene-BPO after 2 weeks of treatment (LE 4) 
Table 8 Efficacy: Papulopustular acne - top. therapy vs. sys. therapy 
 Isotretinoin  
Clindamycin/ 
erythromycin/ 
lymecycline 
Tetracycline (t) Doxycycline (d) 
Minocycline 
(m) 
Azelaic acid 
(aa) ne ne ne ne ne 
BPO ne ne ne ne BPO = m LE 3 
Clindamycin (c) ne ne c = t LE 1 ne 
c > m 
LE 4 
Erythromycin (e) ne ne e > t LE 3 ne ne 
Erythromycin+ 
zinc (ez) ne ne 
ez ≥ t 
LE 3* ne 
ez > m 
LE 4 
Tetracycline (t) ne ne ne ne ne 
LE=level of evidence; ne=no evidence; sys.=systemic; top.=topical 
* erythromycin + zinc liquid > sys. tetracycline (LE 3); erythromycin + zinc gel > sys. tetracycline (LE 3) 
Table 9 Efficacy: Papulopustular acne - sys. monotherapy vs. antibiotics/ isotretinoin/ 
zinc 
 
Placebo/ 
vehicle (v) 
Doxycy-
cline (d) 
Erythro-
mycin (e) 
Lymecy-
cline (l) 
Minocy-
cline (m) 
Tetracy-
cline (t) 
Isotre-
tinoin (i) 
Zinc 
(z) 
Clindamycin 
(c) 
c > v 
LE 3 ne ne ne ne 
t > c 
LE 3 ne ne 
Doxycycline 
(d) 
conflicting 
LE 3* X 
e = d 
LE 3 ne 
m = d 
LE 3 ne ne ne 
Erythro-
mycin (e) ne X X ne ne 
e = t 
LE 3 ne ne 
Lymecycline 
(l) 
l > v 
LE 3 X X X 
m = l 
LE 4 ne ne ne 
Minocycline 
(m) 
m > v 
LE 1 X X X X 
m = t 
LE 2 ne 
m > z 
LE 3 
Tetracycline 
(t) 
t > v 
LE 1 X X X X X ne 
t > z 
LE 3 
Isotretinoin 
(i) 
i > v 
LE 4 X X X X X X ne 
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Zinc (z) z > v LE 1 X X X X X X X 
LE=level of evidence; ne=no evidence; sys.=systemic  
* doxycycline 20mg BID or 0.6mg/kg QD = placebo (LE 3); doxycycline 1.2mg/kg or 100mg QD ≥ 
placebo (LE 3); doxycycline 2.4mg/kg > placebo (LE 3) 
* doxycycline 20mg BID or 0.6mg/kg QD = placebo (LE 3); doxycycline 1.2mg/kg or 100mg QD = 
placebo (LE 1); doxycycline 2.4mg/kg > placebo (LE 3) 
Table 10 Efficacy: Papulopustular acne - sys. therapy vs. sys.-top. combination 
f.c.=fixed combination, LE=level of evidence; ne=no evidence; sys.=systemic; top.=topical 
Combination oral contraceptives (COCs) 
For the previous version of the guideline, due to limited evidence, it was difficult to 
draw conclusions on the differences in efficacy between the anti-androgens. For the 
update, the data summary from the Cochrane Review by Arowojolu et al. [102] was 
used. It found that: “COCs reduced acne lesion counts, severity grades and self-
assessed acne compared to placebo. Differences in the comparative effectiveness of 
COCs containing varying progestin types and dosages, though, were less clear. 
COCs that contained chlormadinone acetate or cyproterone acetate improved acne 
better than levonorgestrel, although this apparent advantage was based on limited 
data. A COC with cyproterone acetate might result in better acne outcomes than one 
with desogestrel; however, the three studies comparing these COCs produced 
conflicting results. Likewise, levonorgestrel showed a slight improvement over 
desogestrel in acne outcomes in one trial, but a second trial found the COC groups 
were similar.” [102] 
Light sources 
Due to the still very limited evidence, the open recommendation for IPL, laser and 
PDT were maintained in the update. The low strength of recommendation for a 
treatment with blue light was kept based on the evidence identified in the 2011 
version of the guideline and confirmed by expert voting. 
5.2.3.2 Safety/ tolerability 
See Table 11 to Table 14 for summary of safety/ tolerability data. 
 
Isotretinoin 
(i) 
Clindamy-
cin (c) 
Doxycycline 
(d) 
Lymecy-
cline (l) 
Tetracy-
cline (t) 
Top. adapalene + sys. 
doxycycline (a-d) ne ne 
a-d = d 
LE 4 ne ne 
Top. adapalene + BPO 
(f.c.) + sys. doxycycline (a-
BPO-d) 
a-BPO-d = i 
LE 4 ne 
d-a-BPO > d 
LE 3 ne ne 
Top. adapalene + sys. 
tetracycline (ta-t) 
i > ta-t 
LE 4 ne ne ne ne 
Top. adapalene + sys. 
lymecycline (a-l) ne ne ne 
a-l > l 
LE 4 ne 
Top. azelaic acid + sys. 
minocycline (aa-m) 
aa-m = i 
LE 4 ne ne ne ne 
Top. tetracycline + sys. 
tetracycline (t-t) ne ne ne ne ne 
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Table 11 Safety/ tolerability: Papulopustular acne - top. therapy vs. top. therapy 
 
Azelaic acid (aa) Adapalene (a) Isotretinoin (i) Tretinoin (t) 
BPO aa > BPO LE 4 
BPO = a 
LE 4 
BPO = i 
LE 4 
BPO = t 
LE 4 / insufficient data* 
Azelaic acid 
(aa) X 
aa > a 
LE 4 ne 
aa > t 
LE 4 
Adapalene 
(a) X X 
a > i 
LE 4 
a > t 
LE 4** 
Isotretinoin 
(i) X X X insufficient data 
LE=level of evidence; ne=no evidence; top.=topical 
* tretinoin 0.025% = BPO 5% (LE 4); BPO 5% vs. tretinoin 0.1% (insufficient data); BPO 5-10% vs. 
tretinoin 0.05% (insufficient data) 
** adapalene 0.1% > tretinoin 0.025% (LE 4); adapalene 0.1% > tretinoin 0.05% (LE 4); adapalene 
0.1% > TMG 0.1% (LE 4) 
Table 12 Safety/ tolerability: Papulopustular acne - top. combinations vs. top. 
therapy/ combinations 
 
BPO 
Ada-
palene 
(a) 
Iso-
tre-
tinoin 
(i) 
Treti-
noin 
(t) 
Clinda-
mycin 
(c) 
Ery-
thro-
mycin 
(e) 
Adapa-
le-ne-
BPO (a-
BPO) 
BPO- 
clinda-
mycin 
(BPO-c) 
Clinda-
mycin- 
tretinoin 
(ct) 
Adapalene-
BPO (a-BPO) 
BPO > 
a-BPO 
LE 1 
a > a-
BPO 
LE 4 
ne ne ne ne X X X 
BPO- 
clindamycin 
(BPO-c) 
BPO-c 
= BPO 
LE 1 
BPO-c 
> a 
LE 4 
ne ne 
BPO-c 
= c 
LE 1 
ne 
BPO-c > 
a-BPO 
LE 4* 
X X 
Clindamycin- 
tretinoin (ct) ne ne ne 
t = ct 
LE 4 
c > ct 
LE 1 ne ne 
BPO-c = 
ct 
LE 4 
X 
Clindamyin-
zinc (cz) ne ne ne ne 
cz = c 
LE 4 ne ne ne ne 
Erythromycin- 
isotretinoin 
(ei) 
ne ne 
ei = i 
LE 4 ne ne 
ei = e 
LE 4 ne ne ne 
Erythromycin- 
tretinoin (et) ne ne ne ne ne ne ne ne ne 
Erythromycin-
zinc (ez) ne ne ne ne 
ez = c 
LE 4 
e > ez 
LE 4 ne 
BPO-c = 
ez 
LE 4 
ne 
LE=level of evidence; ne=no evidence; top.=topical 
* clindamycin-BPO > adapalene-BPO after 12 weeks of treatment (LE 4); clindamycin-BPO > 
adapalene-BPO after 2 weeks of treatment (LE 4) 
Topical monotherapy versus systemic monotherapy 
Topical treatments usually result in local side effects whereas systemic treatments 
cause, among others, mostly gastrointestinal effects. It is therefore difficult to 
accurately compare topical and systemic treatments in terms of safety/ tolerability. 
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Systemic antibiotics 
From the included trials, no clear conclusion can be drawn as to which antibiotic 
treatment has the best safety/ tolerability profile. 
Table 13 Safety/ tolerability: Papulopustular acne - sys. monotherapy vs. sys. 
antibiotics/ isotretinoin/ zinc 
 
Doxycy-
cline (d) 
Erythro-
mycin (e) 
Lymecy-
cline (l) 
Minocy-
cline (m) 
Tetracy-
cline (t) 
Isotreti-
noin (i) Zinc (z) 
Clinda-
mycin (c) ne ne ne ne 
t = c 
LE 4 ne ne 
Doxycy-
cline (d) X 
insufficient 
data ne 
m = d 
LE 4 ne ne ne 
Erythro-
mycin (e) X X ne ne 
t > e 
LE 4 ne ne 
Lymecy-
cline (l) X X X 
l > m 
LE 4 ne ne ne 
Minocy-
cline (m) X X X X 
m = t 
LE 4 ne 
m > z 
LE 4 
Tetracy-
cline (t) X X X X X ne 
insufficient 
data 
Isotre-
tinoin (i) X X X X X X ne 
LE=level of evidence; ne=no evidence; sys.=systemic 
Smith and Leyden [103] performed a systemic review analyzing case reports on 
adverse events with minocycline and doxycycline between 1966 and 2003. As a 
result, they suggest that adverse events may be less likely with doxycycline than with 
minocycline. More severe adverse events seem to appear during treatments with 
minocycline. Doxycycline however, leads to photosensitivity, which is not seen with 
minocycline. 
See also Chapter 5.4.2 Choice of type of systemic antibiotic. 
Combination oral contraceptives 
The included Cochrane review by Arowojolu et al. [102] does not provide definite 
conclusions on tolerability, safety and frequency of adverse events. 
For the use of oral contraceptive, relevant safety aspects such as the risk of 
thrombosis have to be considered. 
Systemic treatments with isotretinoin 
From the included trials, no clear comparison of the safety/ tolerability profiles of 
isotretinoin with other systemic treatments can be made. (For a discussion of 
isotretinoin depression, see Chapter 0) 
Table 14 Safety/ tolerability: Papulopustular acne - sys.-top. combination vs. sys. 
therapy 
 
Isotretinoin (i) Clinda-
mycin (c) 
Doxycycline 
(d) 
Lymecy-
cline (l) 
Tetra-
cycline (t) 
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Top. adapalene + sys. 
doxycycline (a-d) ne ne 
a-d = d 
LE 4 ne ne 
Top. adapalene + BPO 
(f.c.) + sys. doxycycline (a-
BPO-d) 
a-BPO-d = i 
LE 4 ne 
a-BPO-d = d 
LE 4 ne ne 
Top. adapalene + sys. 
tetracycline (ta-t) 
not 
comparable ne ne ne ne 
Top. adapalene + sys. 
lymecycline (a-l) ne ne ne 
l > a-l 
LE 4 ne 
Top. azelaic acid + sys. 
minocycline (aa-m) 
aa-m > i 
LE 4 ne ne ne ne 
Top. tetracycline + sys. 
tetracycline (t-t) ne ne ne ne ne 
f.c.=fixed combination, LE=level of evidence; ne=no evidence; sys.=systemic; top.=topical 
Light sources 
Although in the literature search for the first version of this guideline, there were 
some studies for the treatment of severe nodular / conglobate acne with laser and 
light sources, no clear recommendations could be drawn. The published evidence 
was very scarce.  
5.2.3.3 Patient preference 
The systematic review by Dressler et al. [97] includes two split-face studies reporting 
patient preferences for adapalene over tretinoin (low risk of bias). 
Two cross-over trials evaluated erythromycin versus clindamycin but only one RCT 
found a statistically significant difference for patient preferences for erythromycin 
(unclear risk of bias). 
Two split-face studies reported patient preferences for clindamycin 1%/BPO 
5%/2.5% over adapalene 0.1%/BPO 2.5% (descriptive data only; unclear risk of 
bias). 
5.2.3.4 Other considerations 
For further discussion on the use of isotretinoin as a first-line treatment for severe 
papulopustular acne, see Chapter 5.4.3. 
The expert group feels strongly that the effectiveness seen in clinical practice is 
highest with systemic isotretinoin, although this can only be partly supported by 
published evidence. Strong expert voting also took perceived lower relapse rates 
after treatment with isotretinoin into consideration. 
5.3 Treatment of severe nodular/ conglobate acne 
5.3.1 Recommendations for severe nodular/ conglobate acne 1 
High strength of recommendation 
Oral isotretinoin is strongly recommended as a monotherapy for the treatment of 
severe nodular/ conglobate acne. 
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Medium strength of recommendation 
Systemic antibiotics 2,3 in combination with the fixed-dose combination of adapalene 
and BPO or in combination with azelaic acid can be recommended for the treatment 
of severe nodular/ conglobate acne. 
 
Low strength of recommendation 
Systemic antibiotics 2,3 in combination with adapalene 4,5 or BPO 5 can be 
considered for the treatment of severe nodular/ conglobate acne. 
For females: Hormonal antiandrogens in combination with systemic antibiotic 2,3 and 
topicals (apart from antibiotics) can be considered for the treatment of severe 
nodular/ conglobate acne. 
For females: Hormonal antiandrogens in combination with a topical treatment can be 
considered for the treatment of severe nodular/ conglobate acne. 
 
Open recommendation 
Due to a lack of sufficient evidence, it is currently not possible to make a 
recommendation for or against treatment with IPL or laser in severe nodular/ 
conglobate acne. 
Although PDT is effective in the treatment of severe nodular/ conglobate acne, it 
cannot yet be recommended due to a lack of standard treatment regimens that 
ensure a favourable profile of acute adverse reaction. 
 
Negative recommendation 
Topical monotherapy is not recommended for the treatment of conglobate acne. 
Oral antibiotics are not recommended as monotherapy for the treatment of severe 
nodular/ conglobate acne. 
Oral anti-androgens are not recommended as monotherapy for the treatment of 
severe nodular/ conglobate acne. 
Artificial UV radiation sources are not recommended for the treatment of severe 
nodular/ conglobate acne. 
Visible light as monotherapy is not recommended for the treatment of severe 
nodular/ conglobate acne. 
1
 Limitations can apply that may necessitate the use of a treatment with a lower strength of recommendation 
as a first line therapy (e. g. financial resources/ reimbursement limit, legal restrictions, availability, drug 
licensing). 
2
 Prescribers of antibiotics should be aware of the potential risk of the development of antibiotic resistances . 
3
 doxycycline and lymecycline (see Chapter 5.4.2), limited to a treatment period of three months 
4
 only studies found on systemic AB + adapalene; isotretinoin and tretinoin can be considered for combination 
treatment based on expert opinion  
5
 indirect evidence from severe papulopustular acne  
5.3.2 Reasoning 
General comment: Very few of the included trials (described below) looked 
specifically at patients with nodular or conglobate acne. As a source of indirect 
evidence, studies of patients with severe papulopustular acne were used and the 
percentage in the reduction of nodules (NO) and cysts (CY) in these studies was 
used. In case of use of such indirect evidence, the strength of recommendation was 
downgraded for the considered treatment options. 
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Systemic isotretinoin shows superior efficacy in the treatment of severe nodular/ 
conglobate acne compared with systemic antibiotics, in combination with a topical 
treatment systemic antibiotic. 
The expert group considered that the greatest effectiveness in the treatment of 
severe nodular/ conglobate acne in clinical practice is seen with systemic isotretinoin. 
This can only be partly supported by published evidence, due to the scarcity of 
clinical trials in conglobate acne. 
In the experts’ opinion, safety concerns with isotretinoin are manageable if treatment 
is properly initiated and monitored. Patient benefit with respect to treatment effect, 
improvement in quality of life and avoidance of scarring outweigh the side effects. 
5.3.2.1 Efficacy 
See Table 15 for summary of efficacy data. Please see methods report for 
explanation of assessment strategy. 
Systemic monotherapy versus placebo 
Systemic isotretinoin has superior efficacy compared with placebo [104] (LE 4*). 
*
 There is only one trial comparing systemic isotretinoin with placebo in nodular/  conglobate acne resulting only 
in LE 4. However, there are multiple trials comparing different dosage without a placebo group and following 
expert opinion, there is no doubt about its superior efficacy.  
Systemic monotherapy versus systemic monotherapy or combination 
See Table 15 for summary of efficacy data. 
Table 15 Efficacy: Nodular/ conglobate acne 
 
Sys. isotretinoin (si) Sys. tetracycline (st) 
Adapalene + tetracycline (a-t) si = a-t LE 4 ne 
Azelaic acid + minocycline (aa-m) si = aa-m LE 4 ne 
Sys. tetracycline (st) si > st LE 3 X 
Top. clindamycin (tc) ne st > tc LE 3 
LE=level of evidence; ne=no evidence; sys.=systemic; top.=topical 
Light sources 
Due to insufficient evidence, it is not currently possible to make a recommendation 
for or against treatment with IPL, laser or PDT in conglobate acne. See also 5.2.3.1. 
5.3.2.2 Safety/ tolerability 
See also Chapter 5.2.3.2 on the tolerability/ safety of papulopustular acne 
treatments. 
From the trials specifically investigating severe nodular/ conglobate acne, very little 
information is available to compare the different treatment options. Almost all patients 
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suffer from xerosis and cheilitis during treatment with isotretinoin, whereas systemic 
antibiotics more commonly cause gastrointestinal adverse events. 
5.3.2.3 Patient preference 
The systematic review by Dressler et al. [97] did not identify any evidence on the 
treatment preferences of patients suffering from conglobate acne. 
5.3.2.4 Other considerations 
For comment on EMA directive see also Chapter 5.4.3. 
5.4 General considerations 
5.4.1 Choice of type of topical retinoid 
Adapalene should be selected in preference to tretinoin and isotretinoin. 
5.4.1.1 Reasoning 
All topical retinoids show comparable efficacy against IL (see Chapter 5.2.3.1), 
whereas against NIL the evidence is conflicting (see Chapter 5.1.2.1). 
Among the topical retinoids, adapalene shows the best tolerability/ safety profile 
followed by isotretinoin and tretinoin (see Chapter 5.2.3.2). 
Patient preference favours adapalene over tretinoin (see Chapter 5.2.3.3). 
5.4.2 Choice of type of systemic antibiotic 
Doxycycline and lymecycline should be selected in preference to minocycline and 
tetracycline. 
5.4.2.1 Reasoning 
5.4.2.2 Efficacy 
Doxycycline, lymecycline, minocycline and tetracycline all seem to have a 
comparable efficacy against IL (see Chapter 05.2.3.1). 
Tetracycline showed better efficacy compared to clindamycin and comparable 
efficacy with erythromycin. 
5.4.2.3 Safety/ tolerability 
From the included trials, no clear results can be drawn as to which antibiotic 
treatment has the best safety/ tolerability profile. 
Smith and Leyden [103] performed a systemic review analyzing case reports on 
adverse events with minocycline and doxycycline between 1966 and 2003. As a 
result, they suggest that adverse events may be less likely with doxycycline than with 
minocycline. More severe adverse events seem to appear during treatments with 
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minocycline. Doxycycline however, leads to photosensitivity, which is not seen with 
minocycline. 
See also Chapter 5.4.2 Choice of type of systemic antibiotic. 
The most frequent ADRs for doxycycline are manageable (sun protection for 
photosensitivity and water intake for oesophagitis), whereas the most relevant side 
effects of minocycline (hypersensitivity, hepatic dysfunction, lupus like syndrome) are 
not easily managed [105]. 
The phototoxicity of doxycycline is dependent on dosage and the amount of sun light 
[106, 107]. 
There is little information on the frequency of ADRs with lymecycline. Its phototoxicity 
has been reported to be lower than with doxycycline and its safety profile is 
comparable to that of tetracycline [105, 108]. 
More severe drug reactions are experienced during treatment with minocycline 
compared with doxycycline, lymecycline and tetracycline. 
5.4.2.4 Patient preference/ practicability 
Doxycycline, lymecycline and minocycline have superior practicability compared with 
tetracycline due to their requirement for less frequent administration. 
5.4.2.5 Other considerations 
The use of systemic clindamycin for the treatment of acne is generally not 
recommended as this treatment option should be kept for severe infections. 
5.4.3 Considerations on isotretinoin and dosage 
The evidence on the best dosage, including cumulative dosage, is rare and partly 
conflicting. In most trials, higher dosages have led to better response rates whilst 
having less favorable safety/ tolerability profiles. Attempts to determine the 
cumulative dose necessary to obtain an optimal treatment response and low relapse 
rate have not yet yielded sufficient evidence for a strong recommendation. The 
following recommendation is based more on expert opinion, than on existing 
published trials. 
For severe papulopustular acne/ moderate nodular acne, a dosage of systemic 
isotretinoin of 0.3 - 0.5 mg/kg can be recommended. 
For conglobate acne a dosage of systemic isotretinoin of ≥0.5 mg/kg can be 
recommended. 
The duration of the therapy should be at least 6 months. 
In case of insufficient response, the treatment period can be prolonged. 
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5.4.4 Oral isotretinoin considerations with respect to EMA directive 
Bettoli/ Layton/ Ochsendorf/ Bukvić Mokos 
The current European Directive for prescribing oral isotretinoin differs from the 
recommendations given in this guideline. 
The EU directive states: “oral isotretinoin should only be used in severe acne, 
nodular and conglobate acne, that has or is not responding to appropriate antibiotics 
and topical therapy” [109]. The inference of this being that isotretinoin should now not 
be used as first-line therapy. 
After almost three decades of experience with oral isotretinoin, the published data 
and opinion of many experts, including the authors of the EU Acne Guideline, support 
systemic isotretinoin being considered as the first-choice treatment for severe 
papulopustular, moderate nodular, and severe nodular/ conglobate acne [13, 110-
112]. Acne treatment guidelines written some years ago advocated the use of oral 
isotretinoin “sooner rather than later” [113]. It is recognized that reduction in 
inflammatory acne may prevent the occurrence of clinical and psychological scarring, 
improving quality of life and in some cases reducing depression [114, 115]. Delaying 
the use of oral isotretinoin, which the group considers to be the most effective 
treatment for severe acne, poses a significant ethical problem. Although comparative 
trials are missing, clinical experience confirms that the relapse rates after treatment 
with isotretinoin are the lowest among all the available therapies. 
Unfortunately the European Directive, although not supported by convincing 
evidence-based data, reached a different conclusion. Theoretically, in EU countries 
clinicians are free to prescribe drugs, such as oral isotretinoin, according to their 
professional experience and clinical judgment. However, in the event of any medical 
problems, clinicians could be deemed liable if they have failed to follow 
recommended prescribing practice [116]. 
There are a number of good reasons why systemic isotretinoin should be considered 
as the first-choice treatment for severe acne, including high levels of clinical 
effectiveness, prevention of scarring and improvement of a patient’s quality of life. 
The EMA recommendations include the following points: 
1. To start at the dosage of 0.5 mg/kg daily. 
2. Not recommended for patients under 12 years of age. 
3. To monitor laboratory parameters, primarily liver enzymes and lipids, before 
treatment, 1 month after starting and every 3 months thereafter. 
4. To avoid laser treatment, peeling and wax epilation for at least 6 months after 
stopping therapy. 
The European Guideline group supports these recommendations of the EMA, 
although expert opinion suggests that being less than 12 years old (point 2) is not 
necessarily a contraindication for the use of isotretinoin. 
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Two areas which are potentially open for future review include dosing regimens and 
abnormal wound healing as a result of oral isotretinoin. 
Dosing regimens 
It has been demonstrated that starting with a low dose (0.1-0.2 mg/kg/day) of 
isotretinoin and progressively increasing to the highest tolerated dose may reduce 
risk and severity of acne flare-ups and facilitate management of and reduce side 
effects [117]. Over the last few years there have been an increasing number of 
reports on oral isotretinoin in more mild to moderate disease in which alternative 
dosing regimens have aimed to achieve efficacy whilst minimizing side effects from 
treatment [118-120]. 
In contrast to this other studies have indicated that higher doses, especially in severe 
nodular/ conglobate acne, are associated with fewer relapse rates [121, 122]. Hence, 
where possible higher dosages are recommended in severe acne and lower dosages 
in less severe forms and as potential maintenance treatment. As differences in 
pharmacokinetics between different brands of isotretinoin cannot be ruled out it is 
advisable to get acquainted with a certain product and to use this same preparation 
throughout a treatment period. 
Abnormal wound healing  
Current recommendations to avoid acne scar repair procedures within 6 months post 
oral isotretinoin arose from reports in the mid 1980's of delayed wound healing and 
hypertrophic scarring with conventional and argon laser dermabrasion. More recent 
small studies suggest that resurfacing procedures do not always impair wound 
healing despite treatment being performed during oral isotretinoin treatment or early 
after cessation of isotretinoin [123]. The results from these studies are confounded by 
small numbers and information bias (lack of blinding and lack of validated 
assessments in particular) and a lack of control for confounding variables and 
selection and publication bias. 
The group did not identify any evidence to support the avoidance of laser therapy, 
wax epilation and peeling for at least 6 months after isotretinoin treatment (point 4) 
[116]. However, the authors acknowledge that oral isotretinoin could interfere with 
wound healing albeit relatively rare. As further evidence emerges recommendations 
to avoid acne scar repair procedures within 6 months post isotretinoin should be 
reconsidered. Earlier treatment of scarring may provide hope that this issue can be 
effectively addressed on a timely basis. 
5.4.5 Consideration on isotretinoin and the risk of depression 
Nast 
It is recommended to assess prior symptoms of depression as part of the medical 
history of any patient before the initiation of isotretinoin and during the course of the 
treatment. 
It is recommended to inform patients about a possible risk of depression and suicidal 
behaviour. 
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A search for systematic reviews was performed to assess the risk of depression 
during the treatment with isotretinoin. Published systematic reviews come to different 
conclusions. All currently existing reviews have methodological limitations with 
respect to their stringency of inclusion and exclusion criteria and systematic reporting 
of identified studies. 
The systematic review by Marqueling et al. [124] reported that rates of depression 
among isotretinoin users ranged from 1 % to 11 % across trials, with similar rates in 
the oral antibiotic control groups. Overall, included trials comparing depression 
before and after treatment did not show a statistically significant increase in 
depression diagnoses or depressive symptoms. Some, in fact, demonstrated a trend 
toward fewer or less severe depressive symptoms after isotretinoin therapy. This 
decrease was particularly evident in patients with pre-treatment scores in the 
moderate or clinical depression range. No correlation between isotretinoin use and 
suicidal behaviour was reported, although only one retrospective trial presented data 
on this topic. 
A systematic review by Bremner et al. [125] took a variety of aspects into 
consideration: 1) case reports; 2) temporal association between onset of depression 
and exposure to the drug; 3) challenge-rechallenge cases; 4) class effect (other 
compounds in the same class, like vitamin A, having similar neuropsychiatric effects); 
5) dose response; and 6) biologically plausible mechanisms. It concluded that the 
literature reviewed is consistent with an association between isotretinoin 
administration, depression and suicide in some individuals. 
In the light of continued uncertainty with respect to the isotretinoin, depression and 
suicidal behavior, caution and patient information appears reasonable. 
5.4.6 Risk of antibiotic resistance 
Simonart/ Ochsendorf/ Oprica/ Lomholt 
Treatment of acne with longer courses of topical or systemic antibiotics may lead to 
the induction of antibiotic resistance. This may contribute to the burden of extra 
deaths and hospital days due to antibiotic resistant pathogenic bacteria that poses a 
serious problem in the world today, including in Europe. It is well known that one 
broad spectrum antibiotic can select for multi-resistance against a number of different 
antibiotics [126]. Furthermore it has been shown, that even low concentrations of 
antibiotics well below the MIC value may select for even high-level resistance [127, 
128]. The use of antibiotics to treat acne may lead to resistance in local P. acnes and 
other local cutaneous bacteria including staphylococci, but importantly, also in 
members of the patients total microbiome on skin and mucosal surfaces. Resistance 
may spread from non-pathogenic to pathogenic species. 
The first relevant changes in P. acnes antibiotic sensitivity were found in the USA 
shortly after the introduction of the topical formulations of erythromycin and 
clindamycin. The molecular basis of resistance, via mutations in genes encoding 23S 
and 16S rRNA, are widely distributed [129]. However, the development of strains with 
still unidentified mutations suggests that new mechanisms of resistance are evolving 
in P. acnes [129]. Combined resistance to clindamycin and erythromycin is much 
more common (highest prevalence 91 % in Spain) than resistance to the 
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tetracyclines (highest prevalence 26 % in the UK) [130]. Use of topical antibiotics can 
lead to resistance largely confined to the skin of treated sites, whereas oral 
antibiotics can lead to resistance in commensal flora at all body sites [131]. 
Resistance is more common in patients with moderate-to-severe acne and in 
countries with high outpatient antibiotic sales [132]. Resistance is disseminated 
primarily by person-to-person contact, and so the spread of resistant strains by the 
treating physicians and by family and friends occurs frequently [12, 129, 130]. 
Although some data suggest that resistant isolates disappear after antibiotic 
treatment is stopped [133, 134], other data suggest that resistance persists and can 
be reactivated rapidly [135]. 
There has been an increasing number of reports of systemic infections caused by 
resistant P. acnes in non-acne patients, e. g. post-surgery [132]. In addition, a 
transmission of factors conferring resistance to bacteria other than P. acnes is 
described [136, 137]. Although antibiotic use in acne patients has been shown to be 
associated with an increased risk of upper respiratory tract infection and with an 
increased carriage of S. aureus [138], the true clinical importance of these findings 
requires further investigation. 
It has been argued that the most likely effect of resistance is to reduce the clinical 
efficacy of antibiotic-based treatment regimens to a level below that which would 
occur in patients with fully susceptible flora [130, 139]. Some trials have suggested a 
clear association between P. acnes resistance to the appropriate antibiotic and poor 
therapeutic response [130, 139]. There is a gradual decrease in the efficacy of topical 
erythromycin in clinical trials of therapeutic intervention for acne, which is probably 
related to the development of antibiotic-resistant propionibacteria [101]. In contrast, 
there is so far no evidence that the efficacy of oral tetracycline or topical clindamycin 
has decreased in the last decades [101, 140, 141]. However recent studies show a 
complex population of P. acnes with diverse virulence potential and antibiotic 
resistance patterns. This may explain the difficulties in predicting the clinical effects 
of antibiotic treatment of acne [142]. 
Since P. acnes is the major skin commensal bacterium found in both acne and 
healthy skin, the strain-level analysis is important to help understand the role of 
P. acnes in acne pathogenesis and in skin health. It has been demonstrated that the 
strain population subtypes or clonotypes were significantly different in acne patients 
and healthy controls [85, 88]. This data could help determine if therapeutic 
modulations of the local P. acnes flora can return the host to a state of health and 
may open for new treatment options. 
Studies on P. acnes resistance have highlighted the need for treatment guidelines to 
restrict the use of antibiotics in order to limit the emergence of resistant P. acnes 
strains. Data indicate that the combination of topical antibiotics with BPO may 
prevent the development of resistance in local P. acnes and staphylococci [143-148]. 
However, it is not known if resistance may develop in the periphery or outside the 
treatment zone due to antibiotic gradients or if a low level of systemic absorption can 
lead to resistance on mucosal surfaces [149, 150]. There is not good evidence that 
the combination of local antibiotics with retinoids or zinc is efficient to prevent local 
resistance in P. acnes and no data is available on the effect on other cutaneous or 
mucosal bacteria [148, 151-154]. 
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It is claimed that low dose systemic doxycycline treatment of acne does not induce 
bacterial resistance [155]. From a microbiological standpoint this is highly surprising 
and more studies are needed to confirm this. In particular one study showed 
development of resistance in subgingival plaques during low dose doxycycline 
treatment of periodontidis [156]. 
As a consequence, the use of systemic antibiotics and topical antibiotics should be 
limited (both indication and duration) and topical antibiotics should preferably be used 
in combination with BPO and avoided as monotherapy. Other recommendations 
include stricter cross-infection control measures when assessing acne in the clinic 
and combining systemic antibiotic therapy with topical broad-spectrum antibacterial 
agents, such as BPO [12, 53, 130]. 
Deleted: n
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6  Maintenance therapy 
Summary of therapeutic recommendations for maintenance therapy with 
respect to acne type before induction therapy 
Recommendations are based on available evidence and expert consensus. Available 
evidence and expert voting lead to classification of strength of recommendation. 
A maintenance treatment, especially for the patients with “particular need for a 
maintenance treatment” as defined below, is recommended. 
The low strength of recommendation provided below reflects primarily the lack of 
good evidence as to which is the best treatment and does not put into question the 
need for maintenance therapy in general. 
 
 
Comedonal 
acne 
Mild to 
moderate 
papulopustular 
acne 
Severe 
papulopustular/ 
moderate nodular 
acne 
Severe nodular/ 
conglobate acne 
High strength of 
recommendation - - - - 
Medium strength 
of recommen-
dation 
- - - - 
Low strength of 
recommendation 
Azelaic Acid 
or 
Topical 
Retinoid 2 
Azelaic Acid 
or 
BPO 
or 
Topical Retinoid 
2
 
Adapalene + BPO 
(f.c.) 3 
or 
Azelaic Acid 
or 
BPO 3 
or 
Low Dose Systemic 
Isotretinoin 
(max. 0.3mg/kg/d) 
or 
Topical Retinoid 2 
Adapalene + BPO 
(f.c.) 3 
or 
Azelaic Acid 
or 
BPO 3 
or 
Low Dose Systemic 
Isotretinoin 
(max. 0.3mg/kg/d) 
or 
Topical Retinoid 2 
Alternatives for 
females 1 
- - 
Continued Hormonal 
Antiandrogens 4 + 
Topical Treatment 
(apart from 
antibiotics) 
Continued Hormonal 
Antiandrogens 4 + 
Topical Treatment 
(apart from 
antibiotics) 
1
 low strength of recommendation 
2
 preference for adapalene over isotretinoin / tretinoin 
3
 in case of continuing inflammatory lesions 
4
 refer to national guidelines and EMA recommendations for precautions with respect to risk and durat ion of 
hormonal antiandrogens/combined oral contraceptives 
6.1 Recommendations 
High strength of recommendation 
None 
 
Medium strength of recommendation 
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None 
 
Low strength of recommendation 
Comedonal acne 
Azelaic acid can be considered for the maintenance treatment of comedonal acne. 
Topical retinoid 1 can be considered for the maintenance treatment of comedonal 
acne. 
 
Mild to moderate papulopustular acne 
Azelaic acid can be considered for the maintenance treatment of mild to moderate 
papulopustular acne. 
Topical retinoid 1 can be considered for the maintenance treatment of mild to 
moderate papulopustular acne. 
 
Severe papulopustular/ moderate nodular acne and severe nodular/ conglobate 
acne 
The fixed-dose combination adapalene and BPO 2 can be considered for the 
maintenance treatment of severe papulopustular/ moderate nodular acne and severe 
nodular/ conglobate acne. 
Azelaic acid can be considered for the maintenance treatment of severe 
papulopustular/ moderate nodular acne and severe nodular/ conglobate acne. 
BPO 2 can be considered for the maintenance treatment of severe papulopustular/ 
moderate nodular acne and severe nodular/ conglobate acne. 
Low dose systemic isotretinoin (max. 0.3 mg/kg/d) can be considered for the 
maintenance treatment of severe papulopustular/ moderate nodular acne and severe 
nodular/ conglobate acne. 
Topical retinoid 1 can be considered for the maintenance treatment of severe 
papulopustular/ moderate nodular acne and severe nodular/ conglobate acne. 
For females: Continued hormonal antiandrogens 3 and topical treatment (apart from 
antibiotics) can be considered for the maintenance treatment of severe 
papulopustular/ moderate nodular acne and severe nodular/ conglobate acne. 
 
Open recommendation 
Due to a lack of sufficient evidence, it is currently not possible to make a 
recommendation for or against maintenance treatment with red light, blue light, IPL, 
Laser, PDT or oral zinc. 
 
Negative recommendation 
Topical and/or systemic antibiotics as monotherapy or combination therapy are not 
recommended for maintenance treatment of acne. 
Artificial UV radiation is not recommended for maintenance treatment of acne. 
1
 preference for adapalene over isotretinoin / tretinoin 
2
 in case of continuing inflammatory lesions 
3
 refer to national guidelines and EMA recommendations for precautions with respect to risk and duration of 
hormonal antiandrogens/combined oral contraceptives 
6.2 Background 
Gollnick/ Dréno 
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Acne is a chronic inflammatory disease that can persist for a number of years, and is 
known to have a negative impact on the patients’ quality of life. Scarring is the most 
difficult sequela of the disease and has therefore to be avoided by appropriate early 
intervention using an evidence based treatment strategy. Acne has the general 
tendency to relapse; however, very little data exists regarding the frequency and/or 
severity and/or velocity of relapses. 
The strategy for treating acne today includes an induction phase followed by a 
maintenance phase, and is further supported by adjunctive treatments (light, peeling) 
and/or cosmetic treatments [157]. 
Education about the physiopathology and the treatment procedures of acne can 
enhance patient adherence to maintenance therapy. However, the psychosocial 
benefits of further reconstituting the skin may be the most compelling reason for 
consistent maintenance therapy. It may also be helpful to explain to patients that 
acne is often a chronic disease running over years that requires acute and 
maintenance therapy for sustained remission. 
Definition of maintenance treatment / goals of maintenance treatment 
No standard definition for maintenance treatment exists/is used.  
The European acne guideline version 2011 stated: ‘Maintenance therapy can be 
defined as the regular use of appropriate therapeutic agents to ensure that acne 
remains in remission’. 
Dressler et al. [158] defined ‘maintenance is the treatment period that follows a 
successful induction therapy at the end of which patients had achieved a pre-defined 
treatment goal’.  
The Board of the Global Alliance for better Outcome of Acne (GA) consented the 
following treatment goals: 
- prevention of relapse of more than 10-20% of inflammatory lesions 
- preventing reoccurrence of microcomedones 
- further improvement of postinflammatory hyperpigmentation and atrophic 
scarring 
Identification of patients with particular need for maintenance treatment 
Adapted from a consensus from the Board of the Global Alliance for better Outcome 
of Acne (GA) the following predictive factors for relapse may serve as criteria to 
identify patients with particular need for maintenance therapy: 
- history of severe of acne 
- family history of chronicity of acne/ persisting acne courses 
- tendency for scarring 
- time until clearance during interventional treatment 
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- severe seborrhea 
- early and fast onset courses in young adolescents 
- early and fast onset of conglobate acne in young adolescents 
- patients already having the course of acne tarda or persisting adult acne 
- female patients with endocrinological disturbances (clinical or/and serological). 
- repeated relapse in medical history after previous therapy 
Pathophysiological considerations for the maintenance phase 
It has been shown that microcomedones significantly decrease during the active 
treatment phase but rebound almost immediately after discontinuation of a topical 
retinoid [159]. 
Therefore, a maintenance therapy to reduce the potential of reoccurring visible 
lesions should be considered as part of routine care today. In particular, inflammatory 
lesions are the prominent marker to be suppressed by topical or combined topical 
and systemic treatment as soon as possible. They almost develop from the 
recurrence of microcomedones. 
Efficacy and safety during maintenance therapies 
A systematic review by Dressler et al. [158] identified four randomized controlled 
trials and three non-randomized intervention studies on acne maintenance treatment. 
Three RCTs [160-162] evaluated adapalene 0.1% gel QD maintenance treatment 
compared to placebo over the course of 12, 16 and 24 weeks each. The pooled 
effect of two RCTs evaluating adapalene versus vehicle on ‘number of patients 
maintaining at least 50% improvement achieved in the initial study’ was statistically 
significant based on inflammatory and non-inflammatory lesion count [160, 161]. The 
24-week open RCT by Zang et al. [162] also reported a higher mean percentage 
reduction in total lesion count in the adapalene than in the placebo arm. Adapalene 
showed superior efficacy in maintaining response on NIL and IL compared to 
placebo/ vehicle. 
Poulin et al. [163] assessed the fixed combination adapalene 0.1%/ BPO 2.5% gel 
QD compared to vehicle QD as maintenance treatment. A statistically significant 
difference was found at 12 and 24 weeks based on inflammatory and non-
inflammatory lesion count: adapalene/ BPO fixed combination showed superior 
efficacy on NIL and IL compared to placebo. 
Reported data on tolerability and safety was limited. Tolerability was reported by all 
authors with mild but mostly no burning / stinging, erythema or dryness [158]. 
There is a strong need to develop more standardized study designs to systematically 
assess maintenance therapy for acne. Due to the set inclusion and exclusion criteria, 
many trials reporting on long maintenance treatment could not be included, mostly 
due to the lack of a clearly defined minimum treatment goal which defines 
responders to enter into a maintenance phase. 
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Additional clinical trials 
Recent clinical trials have in particular looked for the effect of maintenance therapy 
on microcomedones. In one of those controlled trials it could be shown that 
adapalene and azelaic acid have been equivalent in preventing relapse and 
suppressing microcomedone recurrence [159, 164]. 
Some other trials which further confirms maintenance therapy to prevent relapse but 
could not be included because of the guideline rules and less defined maintenance 
treatment inclusion criteria in the past (see above) should be mentioned here. In a 
vehicle controlled study by Vender et al. [165] prevention with tretinoin 0.04% gel 
(microsphere) against relapse was shown in patients having been before 
successfully treated by oral isotretinoin. In another prospective, randomized, double-
blind and vehicle-controlled study of 30 patients with acne previously treated with 
isotretinoin a retinoid combination (retinsphere technology Bi-retix) was applied to 
one side of the face and vehicle was applied to the other, once daily, for 3months. 
The relapse rate was significantly lower on the retinoid-treated side compared to the 
vehicle-treated side. 
6.3 Reasoning 
Available evidence indicates efficacy of topical retinoids and adapalene/ BPO over 
vehicle during maintenance treatment. 
Pathophysiological data supports use of topical retinoids and adapalene based on 
their shown efficacy on microcomedones. 
Any use of topical or systemic antibiotics is not recommended on a long-term base / 
during maintenance therapy. 
Duration of long term-treatment 
The following maintenance treatment periods can be considered: 
- 3 to 6 months following clearing after interventional treatment phase can be 
recommended 
- patients with conglobate acne may need long-term maintenance over 6 to 12 
months 
- acne tarda patients may need individual long-term maintenance over years. 
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Disclaimer 
The development of guidelines is a time and resource intensive process and 
currently no public funding is available for European guidelines. In order to be able to 
produce high quality guidelines the EDF uses its membership contributions and asks 
its cooperative partners for support. 
Corporate partners of the EDF have been asked to contribute towards this work. 
[insert other companies], [insert other companies], and [insert other companies] have 
contributed funding for the development of the European evidence-based (S3) 
guideline for the treatment of acne (update 2016) through an educational grant to the 
EDF. Sponsors had no influence on the content of the guideline. Support was given 
independent of any influence on methods or results. Sponsors did not receive any 
information about methods, group members or likely results. The sources of the 
funding will be disclosed to the members of the group and the users of the guideline 
after the finalization of the guideline. 
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